548 related articles for article (PubMed ID: 23974119)
1. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
Tao R; Xiong X; DePinho RA; Deng CX; Dong XC
J Biol Chem; 2013 Oct; 288(41):29252-9. PubMed ID: 23974119
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
3. Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6.
Tao R; Xiong X; DePinho RA; Deng CX; Dong XC
J Lipid Res; 2013 Oct; 54(10):2745-53. PubMed ID: 23881913
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
[TBL] [Abstract][Full Text] [Related]
7. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
[TBL] [Abstract][Full Text] [Related]
8. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
[TBL] [Abstract][Full Text] [Related]
10. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
[TBL] [Abstract][Full Text] [Related]
11. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway.
Dong B; Li H; Singh AB; Cao A; Liu J
J Biol Chem; 2015 Feb; 290(7):4047-58. PubMed ID: 25540198
[TBL] [Abstract][Full Text] [Related]
13. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.
Miyazawa H; Tabeta K; Miyauchi S; Aoki-Nonaka Y; Domon H; Honda T; Nakajima T; Yamazaki K
Lipids Health Dis; 2012 Sep; 11():121. PubMed ID: 22992388
[TBL] [Abstract][Full Text] [Related]
14. G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies.
Hussain Y; Ding Q; Connelly PW; Brunt JH; Ban MR; McIntyre AD; Huff MW; Gros R; Hegele RA; Feldman RD
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):213-21. PubMed ID: 25395619
[TBL] [Abstract][Full Text] [Related]
15. The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells.
Li H; Liu J
Biochem J; 2012 May; 443(3):757-68. PubMed ID: 22288532
[TBL] [Abstract][Full Text] [Related]
16. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
Schiele F; Park J; Redemann N; Luippold G; Nar H
J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
[TBL] [Abstract][Full Text] [Related]
17. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
